






























































immunofluorescence on serum were both negative. Genomic
sequencing showed a single exon KRT5:p.L150P mutation and
single exon KRT14:p.R56C mutation. Dapsone was continued
for 12 months, and he maintained an excellent clinical response.
Validated scales for objective quantitation of EB disease severity
were not available in 2008. However, the improvement docu-
mented with clinical photography is clear (Fig. 1b).
The second patient is a 44-year-old Lebanese male with Junc-
tional EB, of the generalised intermediate subtype, negative for
integrin beta-4 (ITGB4) expression on immunofluorescence
mapping (EB registry number EB-488). His disease is managed
with silicone foam dressings. He also receives haemodialysis for
end-stage kidney disease secondary to bilateral ureteric strictures
related to his EB. This patient presented to our EB service in
February 2019 with a widespread flare of pruritic blisters and ero-
sions (Fig. 1c). At this review, his EB Disease Activity and Scaring
Index (EBDASI)5,6 was elevated, showing activity 51 and damage
58. His Quality of Life in EB (QOLEB) score7 was 14. Following
our experience with the first patient, he was commenced on
25 mg of dapsone orally, twice weekly. A lower dose was used
considering his renal impairment. Each dose was taken on the
day following dialysis for maximum effect. After 2 months, the
dose of dapsone was increased to 25 mg orally, three times per
week. Four months after initiating dapsone, his EBDASI activity
score decreased to 36 and his QOLEB score to 4. Six months after
commencing dapsone, his EBDASI activity score improved fur-
ther to 26 (Fig. 1d). The damage score remained unchanged. The
patient denied adverse effects. He has continued dapsone for
10 months, and his EB remains quiescent.
Inherited EB is a blistering disease with limited treatment
options. It is notoriously difficult to manage, even for the experi-
enced dermatologist. In our two patients, use of oral dapsone
led to rapid and sustained improvement. We believe this is a
novel finding. Dapsone has been used successfully in the simi-
larly named but unrelated autoimmune blistering disease EB
acquisita.8 However, there are no published studies reporting on
oral dapsone as a treatment for inherited EB and this warrants
further investigation. Dapsone may be a valuable and untapped
adjunct therapy for patients with this devastating disease.
The patients in this manuscript have given written informed
consent to the publication of their case details.
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Skin hyperpigmentation index: a





Skin hyperpigmentation is of great concern to people who suffer
from it. It may be endogenous (when the pigments are formed
within the body) or exogenous (when the pigments are applied
externally, for example tattoos). The main endogenous pigments
are melanin (e.g. melanocytic nevi, lentigines) and hemosiderin
(dermite ocre). The activation of melanocytes, due to pregnancy
hormones, sunlight or local inflammations, causes an increase in
the melanin production. Hemosiderin deposition can be caused
by an increased hydrostatic pressure (such as during chronic
venous insufficiency), vasculitis of small skin vessels or vessel
destruction (resulting from sclerotherapy, postsurgical haema-
toma formation and skin-laser therapy).1,2
Measurement of skin hyperpigmentation is clinically impor-
tant in the assessment, follow-up and therapy of hyperpig-
mented lesions. To date, there are no reliable objective methods
for measuring skin hyperpigmentation quantitatively. Here, we
report a novel, practical, unbiased and fully automated method
of quantitively evaluating and documenting skin hyperpigmen-
tation. The introduction of advanced digital image processing
systems such as Image J (NIH, Bethesda, MD) has simplified the
execution of complex operations using clinical imaging. We have
developed a plugin for Image J (see Data S1 and S2), which was
derived from the IHC profiler plugin3,4 using colour deconvolu-
tion and image histogram profiling of brown pixel intensities for
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the automated evaluation of a quantitative skin pigmentation
score (PS). The score ranges from 1 to 4 and is a result of the












1 means no hyperpigmentation, 4 means maximum hyperpig-
mentation. In order to normalize the assessment, we set up an
important sun-protected anatomical marker, the L4 spinous
process, as the reference point. However, other sun-protected
reference points can also be selected in this method. The images
are evaluated with the PS plugin. Clinical or dermoscopic pho-
tographs are taken from the hyperpigmented area of interest and
the reference point in an identical imaging manner. Thereafter,
the skin hyperpigmentation index (SHI) is computed as a ratio
of the PS scores, as shown below. The SHI ranges from 1 (no
hyperpigmentation) to 4 (maximum hyperpigmentation) (see
example in Figs 1 and 2).
SHI ¼ PSArea with hyperpigmentation
PSReference point
In conclusion, this new automated digital imaging analysis
offers new possibilities for further advances in objective clinical
image analysis, by measuring the optical density proportional to
the degree of hyperpigmentation. The disadvantage of only mea-
suring the pigmentation score is that it can vary depending on
skin type and photosetting. Therefore, the calculated SHI with
reference image from the same patient with the same photoset-
ting is necessary to make an objective measurement by reducing
the possible confounding factors. Compared to other quantify-
ing pigmentation grading systems, our method is examiner- and
instrument-independent and can also be applied to different
skin types due to the index calculation.5,6 Therefore, the applica-
tion of our new SHI facilitates an unbiased quantification of skin
hyperpigmentation. It could help clinicians quantify the extent
of hyperpigmentation, which may be useful in assessing the
(a) (b)
(c)
Figure 1 (a, b) Hyperpigmentation of the leg in a patient with chronic venous insufficiency, (c) Control image of a sun-protected site on
the lower back at the L4 level.
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lesions correctly, planning appropriate therapies (such as topical
and laser therapies) and following up on the efficacy of these
therapies.
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Supporting information
Additional Supporting Information may be found in the online
version of this article:
Data S1. Skin Hyperpigmentation Score Plugin for ImageJ
program (JAVA).




Figure 2 Dermoscopic images of selected areas from the hyperpigmented site on the distal lower leg (see circle in Figure 1b) and a con-
trol image from a sun-protected site on the lower back at the L4 level (see circle in Figure 1c). Image analysis and comparison by Image J
and the pigmentation score (PS) plugin. The PS plugin counted the pixels, calculated the percentage contributions, and then declared the
score in the hyperpigmented area (a) as positive and in the reference area (b) as negative. To perform a quantitative comparison, the pig-
mentation score was calculated in figure (a) as 1.9675 and in figure (b) as 1.0215 (see formula in the main text). The skin hyperpigmenta-
tion index (SHI), a ratio of the PSs of the hyperpigmented and non-hyperpigmented sun-protected skin, was calculated as 1.93. All
dermatoscopic pictures were taken by a Nikon D810 digital camera with Dermlite 3 dermoscopy lens.
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